"Drug Resistance" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
| Descriptor ID |
D004351
|
| MeSH Number(s) |
G07.690.773.984
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance".
This graph shows the total number of publications written about "Drug Resistance" by people in this website by year, and whether "Drug Resistance" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 5 | 5 |
| 1999 | 1 | 3 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 6 | 6 |
| 2002 | 1 | 5 | 6 |
| 2003 | 0 | 6 | 6 |
| 2004 | 1 | 4 | 5 |
| 2005 | 3 | 3 | 6 |
| 2006 | 2 | 3 | 5 |
| 2007 | 0 | 3 | 3 |
| 2008 | 3 | 4 | 7 |
| 2009 | 4 | 8 | 12 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 5 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 4 | 5 |
| 2014 | 1 | 3 | 4 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 3 | 6 |
| 2019 | 1 | 7 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 3 | 4 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 3 | 4 |
| 2025 | 0 | 2 | 2 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance" by people in Profiles.
-
Fibrinogen and lipopolysaccharide promote TLR4-dependent glucocorticoid resistance in airway mycosis-driven allergic airway disease. Mucosal Immunol. 2026 Aug; 19(4):100354.
-
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstr?m macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May; 13(5):e284-e296.
-
Whole-brain Mapping Reveals Diet-dependent Neuronal Activation and Selective Resistance to Exogenous FGF21. Endocrinology. 2025 12 05; 167(1).
-
PCM1 is necessary for focal ciliary integrity and is a candidate for severe schizophrenia. Nat Commun. 2020 11 19; 11(1):5903.
-
CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. Mol Ther. 2021 01 06; 29(1):32-46.
-
Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Commun Biol. 2020 07 16; 3(1):386.
-
Genetic variants in toll-like receptor 4 are associated with lack of steroid-responsiveness in pediatric ITP patients. Am J Hematol. 2020 04; 95(4):395-400.
-
CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions. DNA Repair (Amst). 2020 03; 87:102803.
-
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.
-
CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803.